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ABSTRACT 
Spasticity can be one of the most challenging problems for patients with neurologic 
conditions such as cerebral palsy, spinal cord injuries, cerebrovascular accidents, multiple 
sclerosis, traumatic brain injuries, etc. It can lead to a wide variety of problems including 
decreased mobility, decreased quality of movement, interference with normal postural 
reactions, interference with functional activities, and pressure sores. Therefore, the 
medical community has focused on effective treatments for spasticity which do not 
produce overwhelming weakness, spasticity, paralysis, fatigue, and/or muscle atrophy. 
Since the late 1970's, the use of botulinum toxin (BTX-A) injections to decrease spasticity 
has been investigated. 
The purpose of this paper is to review research studies involving the use of BTX-A 
injections for the management of spasticity arising from central nervous system 
dysfunction. This review will focus specifically on: (1) the effectiveness of BTX-A in 
decreasing spasticity, and (2) improvements in functional performance and quality of life 
due to this decrease in spasticity (including increased mobility, increased quality of 
movement, and increased independence in activities of daily living). 
In the majority of studies reviewed, significant decreases in spasticity upon injection of 
BTX-A were reported. These decreases in spasticity caused subsequent increases in active 
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and passive range of motion, and decreases in pain and uncontrolled movements. 
Improvements in ambulation, transfer skills, hygiene skills, positioning ease, and overall 
function were less frequently examined, but reported in approximately half of the studies 
reviewed. Few studies mentioned the changes in quality of life or the increased ability in 
carrying out role functions in daily life following BTX-A injections. Additional research 
studies are needed to quantify the effects of BTX-A injections on functional limitations and 
on quality of life. If research shows that patients obtain improved function following BTX-
A injections, physical therapy may be paramount in helping clients recognize their newly 
found skills. The role of physical therapy following BTX-A injections is an area that 




Spasticity is an intriguing phenomena which spans an array of diagnoses and 
ages. It can be one of the most challenging problems for patients with neurologic 
conditions such as cerebral palsy, spinal cord injuries, cerebrovascular accidents, 
multiple sclerosis, traumatic brain injuries, etc.' Glenn and Whyte' describe 
spasticity as a 
" ... syndrome associated with a persistent increase in the involuntary 
reflex activity of a muscle in response to stretch. Four specific 
phenomena may be variably observed in the constellation of 
spasticity: hypertonia (frequently velocity-dependent and 
demonstrating the "clasp-knife" phenomenon), hyperactive deep 
tendon reflexes, clonus, and spread of reflex responses beyond the 
muscle stimulated." 
The primary consequence of spasticity is abnormal postural tone, a phenomena 
resulting in an exaggerated array of spontaneous motor activity.2 Spasticity may 
ultimately lead to a wide variety of problems including decreased mobility, 
decreased quality of movement, interference with normal postural reactions, 
interference with functional activities, and development of pressure sores.3 
2 
Experimental studies in animals suggest that the tone increase associated with 
spasticity may interfere with longitudinal muscle growth and cause sustained 
reduction of the anatomical muscle length.4,s This may result in the conversion of 
dynamic contractures to fixed permanent contractures. 
Although the characteristics and causes of spasticity differ across various 
neurologic conditions, the ultimate goal for rehabilitation professionals is to 
maximize overall functional performance for individuals with abnormal postural 
tone. Abnormal postural tone refers to the "abnormal reflexes and neuromuscular 
signs associated with impaired movement."2 To maximize function, Perry6 
contended that rehabilitation must emphasize the following areas: (1) contracture 
minimalization, (2) realistic planning, (3) muscle-strength preservation and 
restoration, (4) enhancement of returning control, (5) substitution for permanent 
functional loss. Therapeutic approaches include casting, splinting, positioning, 
physical modalities, motor learning/relearning, orthopaedic procedures, etc.1,3 
Physicians focus on the development of effective treatments for spasticity. 
Active function will assumingly increase with reduction of spasticity, as long as the 
treatment does not produce overwhelming weakness, paralysis, fatigue and/or 
muscle atrophy.1 With effective management of spasticity, soft tissue contractu res 
can also be prevented. Existing procedures utilized by physicians include 
pharmacological management (oral baclofen, diazepam, benzodiazepine, sodium 
dantrolene, phenothiazine), neurosurgical procedures (anterior and posterior 
rhizotomy, selective posterior rhizotomy, cordotomy, intrathecal chemotherapy), 
3 
phenol or baclofen injections, and nerve blocks. 1,3 
It has been argued that the treatment procedures currently being employed are 
unsatisfactory in the successful management of spasticity. Medications often 
produce harmful side effects such as sedation and generalized weakness, and 
cannot be used to selectively reduce harmful spasticity in one muscular area while 
preserving useful spasticity in another.6-9 Neurosurgical procedures and nerve 
blocks are invasive, non-selective, irreversible, and there is a chance that the 
spasticity will re-occur. Intrathecal phenol injections are non-selective, and 
complications may include incontinence, paresthesia, excessive weakness, and 
even death.lO The conservative techniques utilized in physiotherapy to control 
spasticity are often unsuccessful and temporary. 
Physicians and therapists question whether the reduction of spasticity 
automatically results in improved functional performance.2 For example, many 
children with cerebral palsy continue to move using irregular movement synergies 
even after they have undergone selective posterior rhizotomies. If a treatment is 
successful at reducing spasticity but does not increase functional performance, 
critics question its legitimacy. An easily administered treatment which successfully 
controls spasticity and increases functional performance is desired. 
Since the late 1970's, the use of botulinum toxin (BTX-A) injections to decrease 
spasticity has been investigated. 11 It was originally proposed for the correction of 
strabismus, and is now considered the drug of choice for treatment of the following 
conditions: hemifacial spasm, torticollis, essential blepharospasm, and spastic 
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dysphonia. 12 Additional pathologies that are managed with BTX-A injections 
include spastic torticollis, postural tremors, focal dystonias, and other limb 
dystonias. Possible advantages of intramuscular BTX-A injections for the 
management of spasticity include the lack of sensory effects, ability to target specific 
muscle groups, ability to weaken muscles in a graded fashion, and absence of 
caustic chemicals. 
The purpose of this paper is to review research studies involving the use of 
botulinum toxin injections for the management of spasticity arising from central 
nervous system dysfunction. This will enable the researcher to address the 
following issues: (1) the effectiveness of BTX-A in decreasing spasticity, and 
(2) improvements in functional performance due to this decrease. Functional 
performance includes, but is not limited to, increased mobility, increased quality of 
movement and increased independence in activities of daily living. 
This study closely follows the format utilized by Campbell et al 2, regarding the 
effects of intrathecally administered baclofen on function in patients with spasticity. 
Campbell et aF utilized a model developed at the National Center for Medical 
Rehabilitation Research (NCMRR) to determine the functional effects of intrathecally 
administered baclofen. The dimensions of the NCMRR model include: 
(1) pathophysiology, (2) impairments, (3) functional limitations, (4) disabilities. The 
effects of BTX-A will be examined utilizing these four dimensions of the NCMRR 
model. A review of the literature on BTX-A injections will be conducted and 
arranged according to the four dimensions developed by the NCMRR. 
CHAPTER 2 
PATHOPHYSIOLOGY 
Pathophysiology of Spasticity 
The NCMRR model describes pathophysiology as the "cellular and molecular 
process of injury or disease pertinent to a particular condition".2 The 
pathophysiology of spasticity is complex and varies among neurological conditions. 
Spasticity is a distinct type of hypertonia in which there is a velocity-dependent 
opposition to the passive movement of muscles.13,14 The faster the muscle is 
stretched, the more resistance is encountered. Spasticity results from the 
reorganization of spinal cord reflexes released from the brainstem or cortex, and is 
due to disease and/or injury to the central nervous system. 14 In the individual 
without spasticity, the nervous structures within the pyramidal tract exert 
monosynaptic control over anterior horn cells for refined movements, and influence 
tone through actions on brainstem nuclei. Thus, the brainstem, which is primarily 
responsible for unrestrained, primitive reflexes, is controlled through the intricate 
actions of the motor cortex, basal ganglia, and cerebellum. These areas are no 




If brainstem dominance occurs, and primitive reflexes are uninhibited, the 
stretch reflex arc becomes deprived of its normal supraspinal modulation. 6,13 This 
results in pathological overactivity in stretch reflex circuits (i.e. exaggerated stretch 
reflexes). For reasons not completely understood, sensory inputs and lack of 
supraspinal control result in excessive activation of alpha motoneurons controlling 
muscle contraction.2 Hypertonic muscles are the result of this activation. 
Theoretically, drugs which can be used to interfere with the abnormal reflex arc 
and depress excessive activity of the muscle fibers are desirable.13 However, side 
effects and long-term effects must be taken into careful consideration.13 Functional 
performance can be hindered by those antispasticity drugs producing weakness, 
paralysis, fatigue and/or muscle atrophy. 
Characteristics and Actions of Botulinum Toxin Type-A (BTX-A) 
Ingested orally, botulinum toxin causes fatal neuromuscular paralysis and is one 
of the most potent biological poisons known. 15 The botulinum toxin utilized 
commercially, Oculinum, is derived from the type A strain of Clostridium 
Botulinum. 16 These gram-positive, rod-shaped, spore-forming, anaerobic bacteria 
are a family of serologically related neurotoxins including A, B, C1, D, E, F, and 
C.17 Clinically, the unit dose of BTX-A is based on a mouse LDso equivalent, that is, 
the amount of toxin which kills 50 percent of a group of 18-20 mice.17,lB Each vial 
of BTX-A contains 100 mouse units (MU) which is the median lethal dose for a 20 
gram Swiss Webster mouse. On the basis of data obtained in monkeys, it has been 
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estimated that the lethal dose for humans is 625 to 6,250 MU for an adult weighing 
110 Ibs. There have been no reported instances of systemic toxicity resulting from 
injections of botulinum toxin. 18 
During the 1970's, extensive research was conducted on botulinum toxin 
leading scientists to a better understanding of its mechanism of action.17 It was 
recognized that the type A toxin could be utilized clinically to selectively paralyze 
muscles. In fact, scientists discovered it produced a long-term blockade that was 
very similar to surgical denervation, causing muscle paralysis, atrophy, and 
electromyograph ic abnormal ities. 17 
Early studies conducted by Drachman and Price15 focused on quantifying the 
mechanism of action of botulinum toxin. They discovered that "the action of 
botulinum toxin is not due to deficient storage of acetylcholine in vesicles or 
blockade of calcium entry into nerve terminal. Studies suggest that the toxin 
. interferes with the acetylcholine process itself, possibly by blocking exocytosis at 
the release sites." It is now known that BTX-A acts by inhibiting presynaptic 
acetylcholine release at the cholinergic nerve terminals without destroying nerve 
, 
endings, nerve terminals, or neuromuscular junctions. 17 
To thoroughly explain how BTX-A produces its paralyzing effects, it is necessary 
to review normal neuromuscular conduction. Normal neuromuscular conduction 
involves the following steps 19 (see Fig. 1): (1) depolarization of the alpha 
motoneuron causing propagation of an action potential down the nerve axon, (2) 
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Fig. 1 - "Normal" nerve conduction (adapted from Mohr19). A, shows depolarization 
of the alpha motoneuron causing propagation of an action potential (AP) down the 
nerve axon; B, conduction of the AP to the nerve telodendria, which has vesicles 
storing the acetylcholine (ACh) neurotransmitter; C, influx of calcium into the 
telodendria causing binding of vesicles to the presynaptic membrane; D, ACh 
release into the synaptic cleft which binds to receptors on the motor end plate 
membrane. This causes a motor end plate potential and a muscle AP is generated. 
8 
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storing the acetylcholine neurotransmitter, (3) influx of calcium into the telodendria 
causing binding of vesicles to the presynaptic membrane, (4) release of 
acetylcholine into the synaptic cleft, which binds to receptors on the motor end 
plate and causes a motor end plate potential, and (5) generation of a muscle action 
potential with ultimate contraction of the muscle. The inhibitory action of 
botulinum toxin is believed to occur in three steps (see Fig. 2): (1) irreversible and 
rapid binding of the toxin to specific presynaptic receptors on the peripheral 
cholinergic synapses, (2) internalization of the toxin-receptor complex across the 
presynaptic membrane, and (3) inhibition of acetylcholine release by disrupting the 
calcium ion-mediated release of acetylcholine. 18 Consequently, BTX-A effectively 
reduces hyperactivity, producing a functionally denervated muscle, and decreases 
the excessive alpha motoneuron activity which is responsible for spasticity. 
The results of a study conducted by Shaari and Sanders20 provided evidence that 
injecting BTX-A at or near the motor end plate region of the muscle produces the 
most effective paralysis. Maximal paralysis of the spastic muscle occurs several 
days after injection. 16 The resulting paralysis is dose-dependent and reversible over 
time, thus, repeat injections are required. The action of botulinum toxin persists for 
approximately three months in most conditions, with some reported effects lasting 
up to one year. It is believed that muscle recovery is due to intramuscular collateral 
axon sprouting, which plays a major role in re-establishing the integrity of 
neuromuscular transmission. Botulinum toxin binds rapidly to the receptors at the 













Fig. 2 - Mechanism of action of botulinum toxin (adapted from Koman 18); A shows 
irreversible binding of botulinum toxin (BTX-A) to specific presynaptic receptors on 
the peripheral cholinergic synapses; B, internalization of the toxin-receptor complex 
across the presynaptic membrane; C, the inhibition of ACh release by disruption the 
calcium ion-mediated release of ACh. 
10 
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absorption of the toxin occurs.18 
Scott21 was the first to utilize BTX-A therapeutically. After conducting initial 
experiments on non-human primates, he successfully employed BTX-A injections in 
the nonoperative management of strabismus. 
The National Institute of Neurological Disorders and Stroke, and the Office of 
Medical Applications of Research of the National Institutes of Health, convened a 
consensus development conference to officially evaluate the clinical uses of BTX-A 
therapy in November 1990.22 After presentations and discussions by experts in the 
field of botulinum toxin therapy, the panel issued a statement which covered the 
following areas: mechanisms of action, indications and contraindications, safe and 
effective uses, side effects and complications, and further research needs. The 
panel emphasized that botulinum toxin therapy is an invasive, potent, irreversible 
treatment, and should only be administered by licensed, experienced physicians. 
Contraindications to its use include allergy to the drug or infection/inflammation at 
the injection site(s). Side effects to BTX-A are usually transitory, well tolerated, and 
treatable. 
CHAPTER 3 
RESEARCH CONDUCTED ON BOTULINUM TOXIN'S 
EFFECTS ON IMPAIRMENTS 
The NCMRR model described impairments as "derangements of organs and 
organ system functions that directly result from the injury or disease process.,,2 
Most of the studies conducted on botulinum toxin described its effects on the 
musculoskeletal system, specifically, its effects on abnormal postural tone. This 
included spasticity, pain as a result of spasticity, range of motion, strength, 
uncontrolled and abnormal movements, spasms, and extremity 
position i ng. 3,4,7, 11, 12,25-31 
Botulinum Toxin's Effects on Spasticity, 
Spasms, Pain, and Uncontrolled Movements 
Das and Park23 were the first to study the effects of botulinum toxin injections on 
spasticity. The Oswestry scale24 (see Table) was utilized to determine whether 
eight patients with post-stroke spastic hemiplegia had decreased upper extremity 
spasticity after injection of BTX-A into the following muscles: biceps, flexor 
digitorum profundus and flexor carpi ulnaris. The Oswestry scale was designed to 
be administered by experienced physical therapists. The patients responded well to 
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Clinical Rating Scales 
Oswestry Scale 
0- solely spasticity, no willed movement possible 
1 - very severe spasticity, movement very poor 
2 - severe spasticity, movement poor 
3 - moderate spasticity, movement fair 
4 - mild spasticity, movement good 
5 - no spasticity, movement normal 
The Degree of Adductor Tone 
0- no increase in tone 
1 - increased tone, hips easily abducted to 45 degrees by one person 
2 - hips abducted to 45 degrees with mild effort 
3 - hips abducted to 45 degrees by one person with major effort 
4 - two people required to abduct the hips to 45 degrees 
Modified Ashworth Scale 
o - no increase in tone 
1 - slight increase in muscle tone, manifested by a catch and release or by 
minimal resistance at the end of the range of motion when the affected 
part(s) is moved in flexion and extension 
1 +- + slight increase in muscle tone, manifested by a catch, followed by 
minimal resistance throughout the remainder (less than half) of the ROM. 
2 - more marked increase in muscle tone through most of the ROM, but affected 
part(s) easily moved. 
3 - considerable increase in muscle tone, passive movement difficult 
4 - limb rigid in flexion or extension 
Spasm Frequency Scale 
0- no spasms 
1 - 1 or fewer spasms per day 
2 - between 1 and 5 spasms per day 
3 - 5 to less than 10 spasms per day 
4 - 10 or more spasms per day, or continuous contraction 
13 
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the injections, and were affected most noticeably at the flexor digitorum profundus. 
One patient increased from a score of "1" on the Oswestry scale to a score of "4" . 
Another patient increased from a score of "2" to a score of "5". 
Aside from the research conducted by Das and Park23, few studies focused 
specifically on the effects of botulinum toxin injections to decrease upper extremity 
spasticity. Memin et aP' injected BTX-A into the upper extremity muscles of eight 
patients with severe, longstanding spasticity. Although no formal spasticity scale 
was utilized, all eight of the patients experienced a subjective decrease in spasticity, 
and reported that this decrease in tone was "beneficial". Utilizing a visual analog 
scale, five patients reported significant pain relief due to decreased spasticity. 
Snow and colleagues4 were the first to conduct a double blind study evaluating 
the effects of BTX-A. The spastic adductor muscles of nine patients with multiple 
sclerosis were injected. Two physicians independently assessed the patients 
utilizing the Degree of Adductor Tone Scale devised by the researchers (see Table). 
The results indicated that BTX-A toxin significantly reduces leg adductor spasticity 
in multiple sclerosis (p = 0.009). This decrease in spasticity resulted in a significant 
improvement in the ease of nursing care (p = 0.009). In two patients, one nurse 
was able to perform care that required two nurses before injection. In another 
patient, a chronic perineal excoriation became accessible to treatment and was 
successfully healed. 
Benecke25 found similar results in his study of 14 patients with multiple sclerosis. 
The patients had prominent, disabling spasticity of their adductor muscles and were 
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chair-bound or bed-bound. Following the first BTX-A injections, spasticity, spasms 
and pain were significantly decreased (p < 0.001). The pain scores, based on a 
subjective scale ranging between 0 (no pain) and 3 (severe and continuous pain), 
were profoundly decreased. The global functioning score, calculated by summing 
patient scores for spasticity, spasms, and pain for all patients, improved significantly 
following BTX-A injection (p < 0.001). 
The majority of researchers studying BTX-A employed the modified Ashworth 
scale26 (see Table) to measure and report patient spasticity scores before and after 
toxin injection. In a study conducted on 10 patients with spastic drop foot, eight 
patients had decreased spasticity in the injected calf muscles by one to two points.27 
Four of these patients who complained of pain became pain-free after the injections. 
In another study, the soleus, tibialis posterior, and both heads of the gastrocnemius 
muscles were injected in 12 patients with plantar flexor spasticity.28 Eighty-three 
percent of the patients experienced a reduction of calf muscle spasticity after 
injection, and six of the subjects had decreased achilles tendon clonus. An ankle 
foot orthosis was no longer needed by one patient and was used to a lesser degree 
in four subjects. 
The results from a study of 12 patients with upper and lower extremity spasticity 
indicated that every patient who was injected (eight patients in the lower extremity 
muscles, four in the upper extremity muscles) demonstrated a "significant reduction 
of tone" based on the Ashworth scale.29 These patients also experienced 
improvements of movement and posture, and five patients with severe painful 
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spasms noted a decrease in the number and intensity of the spasms. Konstanzer et 
al 30 found similar results; 10 of the 11 patients injected with the toxin showed an 
increase of at least one point on each of the following: Ashworth scale, pain scale, 
and hygienic scale (see Table). 
Case studies were utilized by two researchers to illustrate the effectiveness of 
BTX-A. Borg-Stein et aP provided case studies of two patients with chronic 
progressive multiple sclerosis. Subject one had severe adductor spasms which 
interfered with sleep and caused scissoring during standing. Oral baclofen and 
dantrolene sodium provided only limited relief of the patient's spasticity. Two 
months after BTX-A injection, the patient reported no more spasms at night. The 
subject's adductor tone, based on the Degree of Adductor Tone Scale, decreased 
from a "4" to "2" (see Table). The patient's spasm frequency score decreased from a 
"3" to a "1" (see Table).7 Polo and Jabbari 12 reported a case study involving a patient 
with "painful cramping" and involuntary movements of the left thigh, which were 
refractory to a wide range of therapeutic treatments. The patient experienced a 
complete control of pain, a notable reduction of abnormal leg movements, and a 
distinct decrease of the burst discharges on the EMG for five months following BTX-
A injection into the left quadracep region. 
The largest series of cases studied was reported recently by Dunne et al. 31 Forty 
patients with moderate to severe spasticity of the upper or lower limbs who were 
unresponsive to conventional physical and medical treatments were injected with 
BTX-A. Clinical videotape assessments of spasticity were utilized and outcome 
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measures included Ashworth spasticity and spasm frequency scales (see Table). The 
mean change in the Ashworth spasticity score and the spasm frequency scale was 
1.2 and 2.4 respectively, which indicated a significant decrease in spasticity and 
muscle spasms (p < 0.0001). Pain was reduced in 28 of the 31 patients. Overall, a 
worthwhile benefit occurred in 85% of the patients, and these patients expressed 
the desire to receive the treatment again if necessary. 
Recently, several research studies have focused on the effectiveness of 
botulinum toxin injections for children with spastic cerebral palsy.4,32,33 Cosgrove et 
al4 studied 26 subjects with cerebral palsy, and found that tone was clinically 
decreased in the injected muscles (calves and hamstrings) in all but one patient. 
One child with athetosis had a marked reduction in uncontrolled movements, and 
his parents and physiotherapists reported decreased athetosis in his other limbs as 
wel/. 
Koman et aP2 divided 27 pediatric patients with cerebral palsy into the following 
groups: three non-ambulatory patients with painful paraspinal spasticity which 
interfered with sitting balance, eight non-ambulatory children with lower extremity 
spasticity which interfered with positioning and hygiene, and 16 ambulatory 
patients with spastic hemiplegia or diplegia. The two groups of non-ambulatory 
patients were injected with BTX-A to decrease spasticity in order to reduce pain and 
to facilitate positioning and hygiene. The last group of patients were injected with 
the toxin to improve their gait. Caregivers reported that the children with painful 
paraspinal muscle spasticity "rested more comfortably and could be positioned 
18 
more easily after the BTX-A injections." Pain was reduced in all three children. The 
eight children with lower extremity spasticity exhibited markedly reduced spasticity 
and improved positioning. One patient who could not tolerate bracing before the 
injection was successfully braced after the injection. 
Calderon-Gonzales et aP3 utilized the Ashworth scale to quantify the change in 
spasticity after BTX-A injection. Fifteen children with cerebral palsy were included 
in the study, and it was found that the post-injection scores of muscle hypertonia 
were significantly lower (P < 0.01) than the pre-injection spasticity scores. The 
decrease in hypertonicity persisted for four to six months. The movements most 
significantly changed were hip adduction and knee flexion. Calderon-Gonzales and 
colleagues suggested that in a young child, selective BTX-A injection may allow 
sufficient time to regain muscle length before spasticity returns, thus preventing 
contractu res and deformities. 
Botulinum Toxin's Effects on Passive Movement, Active Movement, and Strength 
Along with a decrease in spasticity, many patients experienced a increased range 
of motion in muscles injected with BTX_A.4,5,23,27,31,33,34 Das and Park23 found that all 
eight of their subjects had increased elbow and wrist active and passive range of 
motion after injection. One patient gained an additional 110 degrees of active and 
160 degrees of passive motion at the elbow joint. Wall et aP4 also studied the 
effect of BTX-A on upper extremity range of motion. Specifically, the potential of 
BTX-A for the treatment of the thumb-in-palm deformity in patients with cerebral 
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palsy was studied. Silhouette tracings were utilized to show that increased hand 
range of motion after injection improved the hand positions in all five patients. 
Although these patients had decreased grip strengths initially after the injection, 
their grip dynamometry scores actually surpassed baseline levels by day 112. 
Increased passive mobility has been anecdotally reported following injection of 
botulinum toxin in two studies involving children with cerebral palsy.s,33 Following 
BTX-A injection into the calf muscles of 23 children, Cosgrove et als determined 
that 74% of their patients had increased passive ankle dorsiflexion, with younger 
patients displaying a greater increase than the older patients. In the same study, 21 
hamstring muscles of 14 patients were injected with BTX-A and, on average, an 
extra 20 degrees of passive extension was gained at the knee (p < 0.01). 
Calderone-Gonzalez and colleagues33 found similar significant increases of passive 
range of motion (p < 0.001) in their patients after BTX-A injections. 
Dunne and colleagues31 used goniometer measurements and blinded videotape 
assessments to determine increases of passive and active lower extremity range of 
motion after BTX-A injection. Goniometer measurements showed a significant 
increase in passive range of joint motion (p < 0.0001), with an average gain of 28 
degrees. Blinded videotape assessments were based on a zero to four point scale 
(zero = limb rigid in flexion; four = norma!), and indicated significant 
improvements in both passive range of motion (p < 0.0001) and active range of 
motion (p < 0.0002). Seventy-five percent of the patients showed at least a one 
grade improvement in passive range of joint motion. Improved active movement 
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scores in the lower limbs influenced personal hygiene, transfers, walking, and 
allowed for more comfortable limb positioning. 
Researchers have hypothesized that resolving lower extremity spasticity wi II 
consequentially increase voluntary range of motion and have a variety of positive 
results, however, few studies have systematically evaluated the effects of botulinum 
toxin on active voluntary movement.2 Cosgrove and colleagues4 utilized gait 
analysis to determine the effect of BTX-A on active movement. Following injection 
of BTX-A into spastic calf muscles, there was an average increase of 11 degrees of 
active dorsiflexion (p < 0.05). This improvement of active dorsiflexion allowed 
better ground clearance and more normal patterns of ankle kinematics during gait. 
Following injection of BTX-A into 21 spastic hamstring muscles, patients were able 
to fully extend their knees during late stance. The differences between active knee 
extension before and after injection proved significant (p < 0.01), and there was a 
mean 22 degree gain in knee extension. 
Dengler et aj27 also evaluated the effects of BTX-A injections on active voluntary 
movement. Ten patients with spastic drop foot were treated, and passive and active 
range of motion values were taken before and after the injection using a 
goniometer. Seven patients showed an improvement of the drop foot position at 
rest and an increase in passive dorsiflexion. Of the patients who were assessed for 
freedom of active range of motion, four revealed an increase of active movement by 
an average of eight degrees. Four patients showed an improvement of resting 
supination position and nine showed an improvement of passive pronation in the 
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lower ankle joint. Four patients showed increased active pronation by an average 
of 11 degrees, and three patients had an increased range of active movement 
(supination-pronation) by an average of 10 degrees. Active supination was 
weakened by the toxin in the remaining three subjects. 
CHAPTER 4 
RESEARCH CONDUCTED ON BOTULINUM 
TOXIN'S EFFECTS ON FUNCTIONAL LIMITATIONS 
Functional limitations are defined as "problems with activities of the total body 
or body segments as a result of impairments; they mayor may not be permanent, 
depending on the course or resolution of the inciting process.,,2 Numerous 
researchers have included anecdotal reports of changes in functional limitations as a 
result of BTX-A injection, including positive changes in gait4,18,27,28,31-33, mobility and 
function3,4,23,28,29,31,34, efficiency of transfers and positioning3,32, and ease and 
efficiency of hygiene skills.3,7,11,30 
Botulinum Toxin's Effects on Gait 
Several researchers have emphasized the changes in gait as a result of BTX-A 
injections. Hesse et al 28 provided the most comprehensive study of changes in gait. 
Gait analysis was utilized to focus on the following variables: velocity, cadence, 
stride, stance symmetry, swing symmetry, double support times, and force 
trajectories under the affected and non-affected foot. Following BTX-A injection, 
velocity, stride length, stance symmetry, and length of the trajectory under the 
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affected foot improved significantly (p < 0.01). Cadence, double support times, 
and the trajectory under the non-affected foot also improved, but did not fulfi II the 
chosen significance level of p = 0.01. Seven patients demonstrated better loading 
and push off of the affected limb, and nine patients demonstrated better initial 
contact of the affected limb. As a result of a longer stride length due to reduced 
ankle muscle tone, gait velocity notably improved by a mean of 27% for the patient 
group. The reduction of plantar-flexor spasticity improved the length of the force 
trajectories under both feet, and increased the progression of body and stride length 
during ambulation. 
Mezaki et aP5 reported variable effects on the gait of three patients with spastic 
paraparesis following BTX-A injection. Two patients had improved gait, however, 
the effect was shortlived. Mezaki et aP5 attributed this transient effect to 
compensation by the non-injected muscles for the muscles which were weakened 
upon BTX-A injection. In the third patient, BTX-A injection into the quadriceps 
caused a weakness with exacerbation of gait disturbance. Borg-Stein et al 3 also 
found varied results. They discovered that following injection of the adductor 
muscles in a subject with a "classic" scissored gait pattern, the patient was able to 
walk between parallel bars without scissoring for the first time in several months. 
Two months later, however, the patient reported a new inability to walk between 
parallel bars, which was attributed to knee buckling. 
Dunne and colleagues31 reported that 10 patients had improved gait pattern and 
five patients returned to walking following BTX-A injections into lower extremity 
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musculature. Lindmark's modified motor assessment system36, which assesses 
active movements, repetitive movements, and mobility of all limbs, was utilized to 
measure motor function. It was reported that following BTX-A injection, the 
mobility of 27 patients was significantly increased (p = .007). Dengler et al 27 also 
noted improvements in gait after injection into the calf musculature of ten patients 
with spastic drop foot. The changes in stance and gait were evaluated by 
physiotherapists. Among the six ambulatory patients, three revealed a "remarkable" 
and two a "moderate" improvement in gait. This improvement in stance and 
mobility was attributed to the improvement of joint mobility following BTX-A 
injection. 
All of the studies reviewed involving children with cerebral palsy included 
qualitative measures of gait before and after botulinum toxin injection.5,18)2,33 In 
two separate studies, Koman et aP8,32 utilized several different measures to assess 
lower-extremity function including gait analysis, physical therapy evaluation, 
Biodex evaluation, physician rating scale (PRS), and parent/guardian questionnaire. 
Preliminary results indicated that all of the patients, except for one child with a 
fixed contracture, showed changes in tone of injected muscles. The PRS, which 
measures degree of crouch, degree of equinus foot, position of hindfoot, position of 
knee, speed of gait, and pattern of gait, increased from an average pretreatment 
score of 5.0 to an average post-treatment score of 10.3. This proved a significant 
increase (p < 0.05) and was indicative of improved gait dynamics. Koman and 
associates18 utilized a randomized double blind trial for the follow-up study. 
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Independent physical therapy evaluations of gait analysis films suggested that BTX-A 
treatment improved gait as compared to placebo injections. Biodex measurement 
proved to be an inappropriate evaluation tool for children with cerebral palsy. Post-
treatment PRS scores showed an improved gait pattern in 83% of the patients, and 
the parents/guardians of four of the six children receiving toxin reported that their 
child's gait had improved during the trial. 
Cosgrove and colieaguesS utilized electrogoniometric measurements of sagittal 
plane kinematics at the hip, knee, and ankle to assess gait in children with cerebral 
palsy. Nine of the 19 patients who had potential for gait improvements 
experienced a one to two-level progression in ambulatory status. Three patients 
who were classified as "non-functional" ambulators became "functional" 
ambulators. After six months, six patients continued to have a higher ambulatory 
status than before the toxin injection. Resolution of spasticity with injection into the 
calf and hamstring musculature allowed for better clearance of the foot during the 
swing phase of gait and increased extension of the knee during the stance phase of 
gait. Calderone33 found similar results in three children who received injections 
into their gastrocnemius muscles. These patients were able to achieve active heel-
strike during gait. 
Botulinum Toxin's Effects on Mobility and Function 
Several research studies included data on the effects of botulinum toxin on 
mobility and function. 3,4,23,27,28,32)3 Utilizing the Barthel index, which was 
developed to assess functional independence before and after treatment, Das and 
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Park23 recorded the functional abilities of a sample of ten patients with spasticity 
associated with stroke-related hemiplegia. The test was given every two weeks 
post-injection, and repeated measurements showed "some" improvement of 
functional status. Increased independence in self-care and mobility skills in six 
patients was also observed. The majority of patients increased their pre-injection 
Barthel index score by 10- 15%. 
Hesse et al 28 employed the Rivermead Mobility Index (RMI) to assess leg and 
trunk motor function pre- and post-botulinum toxin injection. The RMI is an 
evaluation tool used to measure physical recovery and progress following a stroke. 
Two weeks after the injection, the Rivermead score increased by one point in three 
patients and by two points in one patient. One patient was able to tap with the 
non-affected foot five times while standing on the affected foot. Two patients could 
achieve dorsiflexion of the ankle with the knee partially flexed and two could 
achieve this with an extended knee. 
Wall and colleagues34 utilized comprehensive videotape assessments to 
determine if BTX-A injections in patients with cerebral palsied hands improved 
gross and fine motor functions. Function of the affected hand was compared with 
function of the unaffected hand in the following tasks: tube transfer pronated, barrel 
opening, card transfer, peg transfer, and overall function. Appearance of the hands 
. was judged from still photographs in five standard positions including: (1) prone, (2) 
midposition, (3) attempted supination, (4) maximum finger and thumb extension in 
prone position, and (5) fisted. The overall functional and cosmetic improvement 
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gained after BTX-A injection was found clinically significant (p = 0.06), and 
persisted throughout the follow-up time of 229 days. "Overall function" and 
"overall appearance" were increased by as much as 43% and 64% respectively, and 
were expressed as percentages compared to the function and appearance of the 
unaffected limb. Parent and teacher reports indicated that the subjects increased 
the spontaneous use of the affected hand both at "work" and at play. Wall et aP4 
concluded that even if re-injection was required on an annual basis to attain 
constant chemodenervation, BTX-A injection of the adductor pollicis is a safe, 
appropriate alternative to surgical release. 
Calderone-Gonzales et al 33 and Cosgrove et al4 reported the effects of BTX-A 
injections on functional outcomes in patients with cerebral palsy. Calderone-
Gonzalez and associates33 measured the functional improvements of six patients on 
the basis of their upright standing positioning. Six children who demonstrated 
severe scissoring during standing were injected in their adductor muscles. The 
scissoring tendency during standing "practically disappeared" in all six children. Six 
children were injected in their knee flexor muscles and were able to straighten their 
knees fully. Likewise, their body posture improved due to a more upright trunk and 
reduced hyperflexion of the hip. Two patients improved in their weight bearing 
ability and were able to initiate unassisted gait. One patient who was injected in 
the posterior tibial muscle improved in varus deviation by 80%, and another patient 
who was injected in the wrist flexor muscles was able to place his hand flat on the 
table with wrist dorsiflexion. This enabled the patient to tolerate a wrist brace for 
the fi rst ti me. 
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Cosgrove and colleagues4 provided subjective data to illustrate the functional 
changes of 26 patients with cerebral palsy. Fourteen children were reported by 
their parents to have displayed "marked" functional improvement, 10 reported a 
"moderate" improvement, one reported "no change", and one reported a "moderate 
deterioration". Based on subjective reports, 92% of the children experienced a 
functional gain following BTX-A injection. 
Borg-Stein et aP reported a case study describing the functional gains 
experienced by a patient whose right hamstring musculature was injected with BTX-
A. During the eight month interval following injection, her short sitting ability 
increased from five-and-a-half minutes of static sitting with assistance to more than 
30 minutes of sitting while performing dynamic upper extremity activities. 
Botulinum Toxin's Effects on Ease and Efficiency 
of Transfer Skills, Positioning, and Hygiene Skills 
Following a pilot study conducted on two patients with severe leg adductor 
spasticity, Snow and colleagues7 found that injection of BTX-A is a useful adjunct in 
overall nursing care. They concluded that botulinum toxin is potentially more 
beneficial for patients with isolated muscle contractions than "traditional" systemic 
drug treatment. Potential applications include: treatment for patients with adductor 
spasticity making care of the perineum difficult, treatment for patients at risk of soft-
tissue necrosis between the legs, and treatment for patients with flexion and 
adduction of the hip causing necrosis over the femoral head. 
Konstanzer and colieagues30 utilized the hygienic rating scale to determine the 
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efficacy of botulinum toxin injections. Ninety-one percent of the patients injected 
experienced an improvement of at least one point in hygienic scales. Memin et al ll 
concluded that "most of the patients reported a benefit in their limb tone and 
referred to a subjective improvement in the activity of daily life and nursing 
following injection". Borg-Stein et aP discussed a patient who experienced 
increased ease of abduction for catheterization, and became independent in 
cleaning and catheterization. 
The effects of BTX-A injections on the ease of positioning and transfers was 
reported by several researchers. 3,12,32 Koman and colleagues32 found that the three 
children injected with BTX-A into spastic paraspinal musculature rested more 
comfortably and could be positioned more easily. The nonambulatory children 
with spastic lower extremities also experienced improved and more comfortable 
positioning post-injection. Borg-Stein et aP discussed a patient whose spasms 
inhibited effective transfers. Eight months following BTX-A injection into the right 
hamstrings, the patient progressed from use of a Hoyer lift to sliding board transfers 
with assistance. However, following injection of BTX-A into the bilateral hip 
adductors, the subject noted increased difficulty with hip flexion in preparation for 
bridging. Polo and Jabbari 12 described the effective treatment of an unusual 
movement disorder with injection of BTX-A. Reduction of the constant movements 
experienced by a patient with painful limb myoclonus enabled easier extremity 
positioning and improved rest. 
CHAPTER 5 
BOTULINUM TOXIN'S EFFECTS ON DISABILITY IN ROLE FUNCTIONS 
The NCMRR model defines "disabilities" as "difficulties in fulfilling the typical 
role functions of daily life in the home, school, workplace, and community.,,2 The 
studies reviewed did not attempt to measure changes in quality of life, or report the 
decline of disability in carrying out life roles in the home and community. Some 
studies did, however, provide an anecdotal account of individuals who experienced 
an increase in ability to participate in daily life role functions. 
Das and Park23 used the Barthel index to assess improvements in self-care 
independence in eight patients injected in their upper extremity musculature. Six 
patients experienced greater independence in activities of daily living and self-care, 
enabling them to more effectively carry out "typical" role functions. 
Grazko and colleagues29 offered two accounts of patients whose daily life role 
functions changed after receiving BTX-A injections. First, a patient with traumatic 
paraplegia complained of severe muscle spasms in the lumbar paraspinal region 
causing reoccurring back pain. The patient was injected between the first and fifth 
lumbar paraspinous muscles, where increased tone was located. The patient's 
spasms were reduced significantly, from more than 10 spasms per week, to between 
two to five spasms per week. Following four injections of BTX-A in a three month 
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period, the patient demonstrated an "improvement in lifestyle". Second, a bed-
ridden patient with advanced multiple sclerosis had severe spasticity of lower-limb 
musculature. Based on results from the Degree of Adductor Tone Scale (see Table), 
BTX-A injections decreased the patient's adductor tone from a "4" to a "2", and 
enabled her to wear an adductor brace for the first time. The patient could then sit 
upright in a chair, which had not been previously possible for several years. 
Increased independence in life activities was described by several 
researchers.3,4,31 Borg-Stein et aP discussed a patient who became more 
independent in basic transfers after injection with BTX-A. Dunne et aPl reported 
that treatment with BTX-A enabled five patients to walk again, thus encouraging 
greater independence. Cosgrove et al4 discussed a patient with athetoid cerebral 
palsy who had particularly satisfying results after injection into the tibialis posterior 
muscle. Preceding injection, the patient was unable to ambulate because of a 
dynamic equinovarus deformity with forefoot adduction. Following injection, the 
patient became able to position his foot plantigrade, producing a stationary foot for 
weight-bearing and allowing independent ambulation for the first time. 
CHAPTER 6 
DISCUSSION AND CONCLUSION 
Discussion 
Clearly, injection of BTX-A into spastic muscles has been demonstrated to 
decrease spasticity and hypertonia for the majority of individuals with multiple 
sclerosis, cerebral palsy, spinal cord injury, spastic paraplegia, and spastic 
hemiplegia. Based on the results obtained from a majority of studies, researchers 
found significant decreases in spasticity based on qualitative data utilizing measures 
such as the Oswestry scale, Degree of Adductor Tone Scale, and Ashworth scale. 
This decrease in spasticity subsequently caused increased active and passive range 
of motion, and decreased pain and uncontrolled movements in several cases. 
To further our understanding of BTX-A and its effects on patients with spasticity, 
it is necessary to go beyond the impairment dimension and the mere assessment of 
movement using single-joint analysis. Patients often face the reality of their 
impairments in the dimensions of functional limitations and disability, which few 
researchers have considered in their studies. Several studies have attempted to 
prove statistically that BTX-A injections improve gait and mobility, however, more 
double-blind, placebo-controlled studies are necessary in these areas to quantify the 
effects and val idate the cost effectiveness of BTX-A treatment. 
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Two of the studies reviewed utilized intricate gait analysis techniques to quantify 
the difference in gait dynamics following BTX-A injections.4,28 Both studies 
indicated substantial changes, enabling their patients to have more "normal" gait 
patterns. Other researchers attempted to quantify changes in gait dynamics utilizing 
a variety of measures, including the physicians rating scale, Lindmark's motor 
assessment, Biodex evaluation, and PT evaluation/observation. Many patients 
appeared to benefit from BTX-A injections, and demonstrated improved gait 
patterns, "easier" ambulation, decreased scissoring, increased ability to clear the 
foot during swing phase, increased ability to extend the knee and bear weight, and 
increased balance.3,27,29,31-33 Due to these positive preliminary results, researchers 
have suggested the need for randomized, controlled clinical trials and detailed 
documentation to define the proper role of BTX-A muscle injections in individuals 
with spasticity. 
The effects of botulinum toxin on disability in role functions is an area which has 
been neglected in research studies. Few studies have mentioned the changes in 
quality of life or the increased ability in carrying out life roles. This is an important 
area to examine, and may help justify the use of BTX-A injections as a viable, 
validated treatment. Of significant importance is quantifying the influence of 
decreased impairment on the dimensions of function and disability. Hence, 
information from these dimensions can be combined to expand our understanding 
of the problem of spasticity and the effects of its resolution.2 
Critics of BTX-A therapy caution that before it is promoted as a "dramatic 
34 
breakthrough" for patients with spasticity, larger randomized controlled trials are 
needed.37,38 Bleck37 questioned how long patients can be cajoled into accepting 
repeated injections over a period of a year or more. Neville38, professor of pediatric 
neurology, wrote recently on the use of botulinum toxin for children with cerebral 
palsy: 
"If (further studies) confirm benefit, then botulinum toxin could 
find several uses in the treatment of the cerebral palsies. These 
include the modification of early patterns of axial asymmetry 
that may influence later development of the spine and hips. It 
could be used early to modify the effects of spasticity on soft 
tissue and bone, thereby reducing the extent of later surgery. 
It could also be used to mimic the effects of possible surgical 
procedures. It could provide a time window for physical, 
including orthotic, interventions ... and it could be used to treat 
focal dystonias within the cerebral palsies, for which surgery 
has gained such a bad reputation ... Botulinum toxin is 
expensive and requires further studies combining careful 
clinical and biomechanical delineation of specific problems 
and methodological rigor." 
During the consensus development held by The National Institute of Health 
(N I H), suggestions were made for further areas of research for BTX-A treatment. 22 
These included continued research in the following areas: 
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"1. Study of the general properties of botulinum toxin including: 
mechanism of action, metabolism and catabolism, mechanisms of 
recovery from paralysis, the target receptors, pharmacology of other 
serotypes, antidotes and blocking techniques, techniques to increase 
the specificity and duration of action, stability and consistency of 
pharmaceutical preparations. 
2. Study of the indications for botulinum toxin treatment including: 
efficacy and safety through controlled clinical trials that use reliable 
outcome measures, optimal measures of clinical benefit, long-term 
and remote effects, does/response relationships and dose schedules, 
causes of primary failure, causes of secondary failure, 
pathophysiology of the diseases treated, physiology of spasm 
reduction in regional muscles that are not directly injected. 
3. Study of contraindications for botulinum toxin treatment including: 
pregnancy and lactation, high doses of chronic maintenance in infants 
and children, diseases of neuromuscular transmission. 
4. Study of the technique of injecting and handling of botulinum 
toxin including: effects on location, dose, concentration, and volume 
on response; dose selection based on objective physiologic or 
anthropometric parameters; the value of EMG for diagnosis, 
localization of the site(s) of administration, and control of dose. 
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5. Study of the side effects and complications of botulinum toxin 
treatment including: antibody formation and its implications, long-
term consequences of repeated injection, the variability in sensitivity 
to injection among different patients and difference muscle groups in 
an individual patient, the mechanism of undesirable regional effects, 
valid and reliable parameters for assessment of outcome, systemic 
effects." 
The NIH emphasized that although botulinum toxin may help decrease the negative 
effects of neurological symptoms (i.e. spasticity, uncontrolled movements, etc.), it is 
not curative in nature. 
Conclusion 
Preliminary results from numerous studies have paved the road for additional 
investigations involving BTX-A injections for individuals with spasticity. The data 
accumulated from current research studies proved that botulinum toxin injections 
are successful in treating the impairments associated with spasticity. Therefore, 
research efforts need to be extended to the other dimensions of the NCMRR model 
such as the effects of BTX-A injections on functional limitations and on disability in 
role functions. 
Research data has suggested that reducing muscle spasticity has the short-term 
benefit of improving function and the long-term benefit of improving longitudinal 
muscle growth.4,s Although BTX-A injections may not permanently remove the 
prospect of surgical intervention, they may delay surgery until the patient is older 
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and at a lower risk for possible complications and recurrence of deformity.32 If 
patients are able to obtain improved function, physical therapy following injection 
of botulinum toxin may play an important role in helping clients recognize their 
newly found skills and maximize the use of these abilities. Physical therapy may be 
the key in helping patients gain benefit from botulinum toxin in the functional and 
disability dimensions, and is another area that warrants additional research. 
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